Navigation Links
Study finds women used 30 percent less analgesia during labor when self-administered

SAN FRANCISCO (February 10, 2011) In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting , in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.

Women often receive a continuous epidural infusion of analgesic during labor. This can lead to prolonged labor and an increase in assisted vaginal delivery. Several pain management studies have been done to begin looking at how much analgesia women use and what their pain experience is like when they are able to administer it themselves.

"We conducted the first double blind study, excluding inductions and including only women who were delivering for the first time, so that we could get a good sample of women with similar labor patterns," said Michael Haydon, M.D., one of the study's authors.

The study was a double-masked trial in which 270 nulliparous women were randomized to one of three groups. Initially, an intrathecal dose of 2 mg bupivicaine/20mcg fentanyl was given followed by maintenance epidural infusion 0.1% bupivicaine/2 mcg/ml fentanyl. Group 1 CEI background only (10 mls/hr); Group 2 CEI+PCEA(CEI at 10 ml/hr plus PCEA 10 ml, 20 min lockout; Group 3 PCEA only (PCEA 10 ml, 20 min lockout). PCEA bolus button was given to each subject and the pump acknowledged the request regardless of group assignment. The primary outcome was dosage of local anesthetic used. Secondary outcomes include obstetric outcomes and maternal satisfaction.

The study results showed that total mg bupivicaine used was less in the PCEA only group compared to CEI; group 1 (74.9 36 mg), group 2 (95.9 52 mg), group 3 (52.8 42 mg) p<.001. No differences were seen in total time of labor; group 1 (8.4 hr), group 2 (7.9 hr), group 3 (8.0 hr) or cesarean delivery; group 1 (26/87), group 2 (23/84), and group 3 (22/85). Number of instrumented vaginal deliveries was slightly higher in subjects with a continuous background infusion; group 1 (8/87), group 2 (8/84), group 3 (3/85). Neither lower extremity strength nor urge to push were affected by method of epidural. Pain with pushing, however, was worse in PCEA only. Median satisfaction scores were similar; 0 (best)-100(worst); group 1: 0 (0-100), group 2: 0 (0-100), group 3: 0 (0-100).

The study concluded that PCEA resulted in 30 percent less analgesia being used while maintaining high maternal satisfaction. There was also a trend toward reduction in instrumented vaginal deliveries in the PCEA only group.

"Though patients in each group showed equal satisfaction, we did note that there was more pain during the final delivery stage in the PCEA group," said Haydon. "The next step is to look at shortening the lock-out intervals between doses, or having the option of administering additional analgesia during the final pushing stage."

Haydon also noted that, in future, he expects the technology to move in the direction of automated analgesia delivery in response to patient need.


Contact: Vicki Bendure
Society for Maternal-Fetal Medicine

Related medicine news :

1. Mouse Study Suggests New Clues to Celiac Disease
2. Many Breakthrough Drugs Come From Publicly Funded Research: Study
3. Johns Hopkins School of Medicine grants $5 million to study cognitive disorders
4. Removing Many Lymph Nodes in Early Breast Cancer Not Always Needed: Study
5. Study Links Brain Molecule to Risk of Major Depression
6. Processed, Fatty Foods May Dumb Down Your Kids: Study
7. Study shows delayed-enhancement MRI may predict, prevent strokes
8. Study: Consumers value safer food more than current analyses suggest
9. Hospitals Often Fail to Follow Up on Tests, Study Says
10. New study to use smart phones to track air pollution exposure
11. Daily Pill Dispensers an Asset in Homes for Elderly: Study
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack ... trailer titles work with any font, giving users limitless opportunities to stylize and ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: